The numbers, in research context
CJC-1295 Ipamorelin dosage as the studies report it — species, route, and timescale, not a protocol.
Research-context doses and half-lives for each half, with the DAC-versus-no-DAC timing kept explicit.
Read this first
This page describes how CJC-1295 Ipamorelin dosing appears in the published research — which doses were given to which animals or volunteers, by which route, and how long each peptide lasts in the blood. It is not a how-to and carries no human protocol. Two things make a single 'dose' impossible to state honestly here: first, the fixed mixed pair has never been through a dosing trial, so there is no studied dose for the combination itself; second, the two halves run on wildly different clocks — the long-acting CJC-1295 (DAC) lingers for days while ipamorelin clears in hours. Everything below is reported in the third person, attributed to a study and a species, with no instruction to anyone. Numbers are written as 'studied at X in [species] by [route]', never as a recommendation.
Cjc 1295 ipamorelin dosage
There is no validated human cjc 1295 ipamorelin dosage for the fixed combination — no controlled trial has ever dosed the pre-mixed pair, so any single figure would be an extrapolation, not a finding. What the literature does provide is single-component dosing. For CJC-1295 (with DAC), human Phase 1 pharmacokinetic studies administered 30 to 90 µg/kg subcutaneously [1], and GHRH-knockout mouse work used 2 µg/day [7]. For ipamorelin, rodent studies used figures such as 100 µg/kg three times daily for bone endpoints and 0.01 to 1 mg/kg intravenously for gut-motility models, with around 1 µg/kg plateauing the GH response in rodents [2][8]; no validated human pharmacokinetic dose for ipamorelin has been published. Those are research observations in named species, not a template for use.
Half-lives — the part that matters most
The half-life split is the single most important number set here. CJC-1295 with DAC runs about six to eight days in humans, because the albumin-bound peptide is detectable in rat plasma beyond 72 hours and clears slowly [1][5]. CJC-1295 no-DAC — Mod GRF (1-29) — is the opposite: on the order of minutes to roughly 30 minutes, like native GRF(1-29), because DPP-IV cleaves it fast [5]. Ipamorelin sits under about two hours in rodent plasma, with the peak GH response near 40 minutes post-dose; no validated human half-life has been published [2]. Pairing a multi-day agent with a sub-two-hour one is exactly why the combination's net GH exposure is uncharacterized for any specific schedule.
Routes and handling, as studied
Across the literature the routes studied are subcutaneous and intravenous, with continuous subcutaneous infusion (osmotic minipump) and intranasal delivery used in rodent pharmacokinetic work [1][2]. On handling: lyophilised (freeze-dried) peptide is stable frozen for extended periods. After reconstitution with bacteriostatic water (sterile water with 0.9% benzyl alcohol as a preservative), aqueous peptide solutions are kept refrigerated at 2–8 °C and degrade over weeks via asparagine deamidation, with degradation products that can be markedly less potent; agitation and repeated freeze-thaw are avoided. GHRH analogues face DPP-IV cleavage in plasma, which is exactly what CJC-1295's substitutions and DAC were engineered to resist [5]. This is standard laboratory-handling context only — not an instruction to prepare or administer anything.
Why no human number appears here
It would be easy to print a 'typical' figure; it would not be honest. The fixed CJC-1295 Ipamorelin combination has never been dosed in a controlled human trial, and ipamorelin has no published human pharmacokinetic dose at all. The CJC-1295 human numbers that do exist come from Phase 1 pharmacokinetic studies designed to characterize the molecule's behavior, not to establish a use protocol [1]. So the responsible thing — and the line this site holds — is to report what was studied, in which species, by which route, and to stop there. For the safety reasoning behind that caution, see the effects page.